Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyKlas Kärre, Rolf Kiessling|Nature|1986Cited by 2.1k
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Guido Kroemer, Enrico Lugli et al.|Oncotarget|2014Cited by 469
Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-SignIsabel Poschke, Rolf Kiessling|Cancer Research|2010Cited by 377
Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor ActivityMaarten A. Ligtenberg, Rolf Kiessling|The Journal of Immunology|2015Cited by 212
Escape Mechanisms in Tumor Immunity: An UpdateLudmila Müller, Graham Pawelec, Rolf Kiessling et al.|Journal of Environmental Pathology Toxicology and Oncology|2002Cited by 15